Inhibrx Biosciences Inc.
INBX · NASDAQ
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 2.19M | -107.99M | -129.12M | -145.23M | -3.62 |
| 2023 FY | 1.80M | 609.00K | -219.22M | -241.36M | -5.12 |
| 2024 FY | 200.00K | -2.09M | -331.45M | 1.69B | 116.58 |
| 2025 FY | 1.30M | -1.18M | -135.03M | -140.06M | -9.04 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 290.88M | 232.82M | 273.87M | 207.10M | 58.06M |
| 2023 FY | 307.89M | 264.39M | 277.92M | 210.14M | 43.50M |
| 2024 FY | 180.77M | 47.18M | 152.60M | 8.05M | 133.58M |
| 2025 FY | 146.48M | 138.49M | 124.22M | 107.01M | 7.99M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | -115.30M | -686.00K | -115.99M | — | 142.56M |
| 2023 FY | -193.31M | -4.59M | -197.90M | — | 4.06M |
| 2024 FY | -194.41M | -2.60M | -197.01M | — | -125.33M |
| 2025 FY | -129.79M | -31.00K | -129.83M | — | -28.38M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 988.26M | 921.50M | — | — | — |
| 2023 FY | 1.79B | 1.72B | — | — | — |
| 2024 FY | 222.93M | 78.38M | — | — | — |
| 2025 FY | 1.22B | 1.21B | — | — | — |
| 2026-12-31 | — | — | — | — | — |
| 2027-12-31 | — | — | — | — | — |
| 2028-12-31 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 1.30M | 638.00K | -27.39M | -28.65M | -1.85 |
| 2025 Q3 | — | -582.00K | -33.81M | -35.26M | -2.28 |
| 2025 Q4 | — | -564.00K | -30.92M | -32.83M | -2.11 |
| 2026 Q1 | — | -537.00K | -30.93M | -33.44M | -2.15 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 212.12M | 143.56M | 186.57M | 106.79M | 68.56M |
| 2025 Q3 | 177.47M | 140.64M | 153.09M | 6.99M | 36.83M |
| 2025 Q4 | 146.48M | 138.49M | 124.22M | 107.01M | 7.99M |
| 2026 Q1 | 183.97M | 205.00M | 161.66M | 5.90M | -21.04M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | -29.95M | — | -29.95M | — | -29.95M |
| 2025 Q3 | -33.82M | -10.00K | -33.83M | — | -33.48M |
| 2025 Q4 | -30.12M | — | -30.12M | — | -28.87M |
| 2026 Q1 | -38.03M | — | -38.03M | — | 37.44M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 220.73M | 140.95M | — | — | — |
| 2025 Q3 | 521.30M | 375.20M | — | — | — |
| 2025 Q4 | 1.22B | 1.21B | — | — | — |
| 2026 Q1 | 1.05B | 892.03M | — | — | — |
| 2026-06-30 | — | — | — | — | — |
| 2026-09-30 | — | — | — | — | — |
| 2026-12-31 | — | — | — | — | — |